UK-listed investment fund Imperial Innovations joins GlaxoSmithKline's SR One, fund manager Invesco Perpetual and Lundbeckfond Ventures, backing the d cancer treatment company.
University-backed and UK-listed investment fund Imperial Innovations has helped PsiOxus Therapeutics, a UK-based cancer treatment company, raise £22m ($34m) in a series B round today.
It was joined in the round by UK-based pharmaceuticals company GlaxoSmithKline’s corporate venturing unit SR One, fund manager Invesco Perpetual and Lundbeckfond Ventures, which is owned by Denmark-based science research body Lundbeck Foundation. Invesco is the largest shareholder in Imperial Innovations, with a 23% stake, according to the Financial Times’ website.
Susan Searle, chief executive…
